68.39 USD
▼-3.99-5.51%
盘后 79.93 0.00%
2026-09-15
市值
$13.37B
市盈率
—
EPS
-3.57
股息率
—
52 周区间
48.78 – 93.42
成交量
3.96M
Beta
0.97
目标价
109.10
52W 低 48.7852W 高 93.42
价格走势
公司简介
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ...
关联新闻
- Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said